
Annual report 2025
added 02-13-2026
Outset Medical Revenue 2011-2026 | OM
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Outset Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119 M | 114 M | 130 M | 115 M | 103 M | 49.9 M | 15.1 M | 2.01 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 130 M | 2.01 M | 81.1 M |
Quarterly Revenue Outset Medical
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 M | - | 28.7 M | - | - | - | 30.6 M | - | 26.3 M | 25.2 M | 22.9 M | 17.2 M | 13.8 M | 11.7 M | 7.19 M | 7.08 M | 2.63 M | 2.87 M | 2.49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.6 M | 2.49 M | 16.3 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
4 B | $ 176.83 | 5.97 % | $ 13.2 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 11.66 | 5.71 % | $ 1.75 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AxoGen
AXGN
|
225 M | $ 34.0 | 9.71 % | $ 1.57 B | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.18 | 2.01 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 281.15 | 1.13 % | $ 7.93 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.62 | 1.67 % | $ 38.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 38.25 | 4.31 % | $ 5.7 K | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 62.56 | 1.15 % | $ 92.6 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
64 M | $ 24.4 | 2.61 % | $ 206 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.17 | 1.1 % | $ 260 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 91.96 | 2.13 % | $ 12.4 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Inogen
INGN
|
349 M | $ 6.67 | -1.91 % | $ 177 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 53.38 | -1.89 % | $ 1.57 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | - | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 87.48 | 2.78 % | $ 3.04 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.01 | 1.59 % | $ 376 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 64.66 | 1.76 % | $ 3.53 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.53 | -1.78 % | $ 66.1 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.14 | 2.22 % | $ 876 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.37 | -0.88 % | $ 126 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.68 | 0.44 % | $ 28.5 M | ||
|
NanoVibronix
NAOV
|
2.56 M | - | - | $ 1.08 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.85 | 1.86 % | $ 353 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | ||
|
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M |